MARC record from Internet Archive

LEADER: 09421cam 2200685Ma 4500
001 ocn614463545
003 OCoLC
005 20220413022918.0
008 020813s2002 njua o 000 0 eng d
006 m o d
007 cr cn|||||||||
040 $aCaPaEBR$beng$epn$cADU$dE7B$dOCLCQ$dCUY$dN$T$dYDXCP$dDKDLA$dOCLCQ$dFVL$dOCLCQ$dSTF$dOCLCQ$dCOCUF$dAGLDB$dMOR$dPIFBR$dOCLCQ$dOCLCF$dVNS$dWRM$dNRAMU$dVT2$dOCLCQ$dREC$dAJS$dOCLCO
019 $a182518914$a285163293$a474661388$a474788340$a647684226$a722615341$a728033047$a756431585$a961585988$a962558915$a988523396$a992011316$a1037732132$a1038668663$a1045439513$a1055370041$a1081293583
020 $a9789812776686$q(electronic bk.)
020 $a9812776680$q(electronic bk.)
020 $a9789812381385$q(alk. paper)
020 $a9812381384$q(alk. paper)
020 $a9789812381392$q(pbk. ;$qalk. paper)
020 $a9812381392$q(pbk. ;$qalk. paper)
020 $z9812381384$q(alk. paper)
020 $z9812381392$q(pbk. ;$qalk. paper)
035 $a(OCoLC)614463545$z(OCoLC)182518914$z(OCoLC)285163293$z(OCoLC)474661388$z(OCoLC)474788340$z(OCoLC)647684226$z(OCoLC)722615341$z(OCoLC)728033047$z(OCoLC)756431585$z(OCoLC)961585988$z(OCoLC)962558915$z(OCoLC)988523396$z(OCoLC)992011316$z(OCoLC)1037732132$z(OCoLC)1038668663$z(OCoLC)1045439513$z(OCoLC)1055370041$z(OCoLC)1081293583
050 4 $aHD9999.B442$bT36 2002eb
072 7 $aBUS$x036000$2bisacsh
082 04 $a332.63/2$221
100 1 $aTang, Chilung Mark,$d1964-
245 14 $aThe essential biotech investment guide :$bhow to invest in the healthcare biotechnology & life sciences sector /$cChilung Mark Tang.
260 $aRiver Edge, NJ :$bWorld Scientific Pub.,$c©2002.
300 $a1 online resource (xix, 261 pages) :$billustrations (some color)
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
588 0 $aPrint version record.
505 0 $aIntroduction. Biotech stock for wealth growth: an essential portion of asset allocation. Biotechnological innovation benefits society. Biotech sector outperforms. Strong fundamentals and product pipelines. Strong growth of revenue and profits. Biotechnology differs from the internet. Stock is essential for wealth growth. Stock for outpacing inflation. Why Biotech? Positive demography: our baby boomer population. Positive demographics trend. Positive technology trend. Big Pharma and the biotech industry -- complementary to each other. Supply demand imbalance? -- ch. 1. The basics of investing. The case for equities. The rule of 72. The power of compounding. Opportunity cost. Relationship between risk and return. Dollar-cost averaging. Purchasing power and inflation -- is a CD really safe? Holding period and risk. Understanding risks. Diversification -- minimizing your investment risk. Past reasons for not investing. Historic return and how much return one should expect. Technical analysis. Investment vehicles available to achieve your goals. Vehicle one: stocks. Vehicle two: bonds. Vehicle three: cash. Vehicle four: mutual funds. Vehicle five: unit investment trust. Vehicle six: managed accounts. Vehicle seven: alternative investment. Asset allocation. Managing your portfolio and wealth -- ch. 2. An introduction to biotechnology and genomics -- ch. 3. Understanding biotechnology invention and the FDA approval process. Part I: Biotechnology inventions and patents. Part II: the FDA approval process for drugs. Stages of the FDA approval process. Drug review glossary -- ch. 4. Introduction to biotech investing. Value investing. Growth investing. The industry life cycle. Characteristics of investing in biotech. Value investing. Biotechnology investment trading rules. Winning biotechnology company attribute list -- ch. 5. How to value and invest in a biotech company. Step one: the economic and business cycle. Step two: industry sector analysis. Biotech industry sector analysis. Step three: biotech company analysis. Valuation: should I buy this biotech stock now? Method 1: relative valuation. Comparisons of P/E ratios. Method 2: discounted cash flow (DCF) analysis. Method 3: sum-of-the-parts valuations. Method 4: dividend discount model (DDM). Method 5: subscriber-based valuations. Method 6: economic value added (EVA). Method 7: yield-based valuations -- valuing market as an example. Qualitative component of the valuation. Risks of biotech companies. Summary: which model is best for valuing biotech companies? Part II: investing in undervalued healthcare biotech -- proactive value investing in healthcare.
505 8 $aCh. 6. Investing in biotechnology mutual funds. Don't put all your eggs in one basket. Purchasing power. Professional management. Asset allocation. Liquidity. Discipline. Dollar-cost averaging. The case for index funds. Why stock or stock mutual funds? The cost of delaying. The benefits of investing in biotech mutual funds -- ch. 7. Healthcare biotech index investing: strategies using exchange-traded-funds (EFTs), biotech iShares, and boxes. The case for index funds. I. Exchange-traded funds (ETFs). Advantages of ETFs. Options strategies for suitable clients. Index-linked ETFs. II. Index investing. III. Strategies using biotech and pharmaceutical BOXES -- ch. 8. Risk management considerations for biotech investors with concentrated equity positions. Alternative 1: retention of the position and associated risks. Alternative 2: liquidation of the position and reinvestment of net proceeds. Alternative 3: hedging, monetizing, and diversification strategies. Conclusion. Glossary -- ch. 9. Managing biotech stock options: your employee benefits. Non-qualified biotech options. Incentive biotech options. Your biotech option plan. Alternative biotech stock acquisition programs. 83(b) election -- ch. 10. An introduction to healthcare biotechnology hedge fund investing. Hedge fund investment styles. Three ways to participate healthcare-biotech hedge funds. Conduct necessary due diligence prior to investing in healthcare hedge fund. Conclusion -- ch. 11. An introduction to healthcare biotechnology private equity investing. I. Healthcare venture capital. Four investment stages of health care-biotech venture capital funding. II. Healthcare buyout funds. III. Special situations in healthcare. Key considerations. How to participate in private equity investing. Five basic ways to participate in healthcare private equity investing. Measuring performance of healthcare biotech private equity funds. Conclusion -- ch. 12. Retirement planning considerations for biotech executives and investors. Changing careers: affecting your retirement savings. Direct and indirect rollovers: spinning your IRA. The tax-deferred rollover. Retirement: strategy -- ch. 13. Charitable disposition of appreciated biotech stocks. I. Private foundations. II. Charitable remainder trusts. Conclusion. III. Alternative charitable gift program through National Philanthropic Trust (NPT) -- ch. 14. Managing your biotech wealth -- estate planning for biotech investors, executives, and founders. Other trust strategies to minimize estate taxes. Conclusion -- Epilogue.
520 $aThis invaluable book tells the reader how to invest in the healthcare biotechnology and life sciences sector, one of the fast-growing sectors of the US economy. Aimed at biotech investors as well as bioentrepreneurs and venture capitalists, it has been written from the perspectives of risk management and asset management/allocation. It strives to teach readers how to fish, rather than giving them fish. The author has over ten years of Wall Street experience in biotech research, investment banking and asset management. He holds an MBA in Finance and a PhD in Biochemistry.
650 0 $aBiotechnology industries$xFinance.
650 0 $aPharmaceutical biotechnology industry$xFinance.
650 0 $aInvestments.
650 7 $aBUSINESS & ECONOMICS$xInvestments & Securities$xGeneral.$2bisacsh
650 7 $aBiotechnology industries$xFinance.$2fast$0(OCoLC)fst00832798
650 7 $aInvestments.$2fast$0(OCoLC)fst00978234
655 0 $aElectronic books.
655 4 $aElectronic books.
776 08 $iPrint version:$aTang, Chilung Mark, 1964-$tEssential biotech investment guide.$dRiver Edge, NJ : World Scientific Pub., ©2002$z9812381384$z9789812381385$w(DLC) 2002033070$w(OCoLC)50447737
856 40 $3ebrary$uhttp://site.ebrary.com/id/10201284
856 40 $3EBSCOhost$uhttp://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=210716
856 40 $3ProQuest Ebook Central$uhttp://public.ebookcentral.proquest.com/choice/publicfullrecord.aspx?p=1681313
856 40 $3EBSCOhost$uhttp://proxy-clarion.klnpa.org/login?url=http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=210716$zClick here to access this full-text ebook. Remote access limited to Clarion University students, faculty, and staff.
856 40 $uhttps://ebookcentral.proquest.com/lib/uvic/detail.action?docID=1681313
938 $aebrary$bEBRY$nebr10201284
938 $aEBSCOhost$bEBSC$n210716
938 $aYBP Library Services$bYANK$n2740401
029 1 $aAU@$b000049162898
029 1 $aAU@$b000052943001
029 1 $aDEBBG$bBV043129800
029 1 $aDEBSZ$b42216724X
029 1 $aNZ1$b12808121
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 601 OTHER HOLDINGS